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OBJECTIVE—Insulin resistance (IR) and cardiovascular disease
may share a common genetic background. We investigated the role
of IR-associated ENPP1 K121Q polymorphism (rs1044498) on car-
diovascular disease in high-risk individuals.
RESEARCH DESIGN AND METHODS—A prospective study
(average follow-up, 37 months) was conducted for major cardio-
vascular events (myocardial infarction [MI], stroke, cardiovascu-
lar death) from the Gargano Heart Study (GHS; n = 330 with type
2 diabetes and coronary artery disease), the Tor Vergata Athero-
sclerosis Study (TVAS; n = 141 who had MI), and the Cardiovas-
cular Risk Extended Evaluation in Dialysis (CREED) database
(n = 266 with end-stage renal disease). Age at MI was investigated
in cross-sectional studies of 339 type 2 diabetic patients (n = 169
from Italy, n = 170 from the U.S.).
RESULTS—Incidence of cardiovascular events per 100 person–
years was 4.2 in GHS, 10.8 in TVAS, and 11.7 in CREED. Hazard
ratios (HRs) for KQ+QQ versus individuals carrying the K121/K121
genotype (KK) individuals were 1.47 (95% CI 0.80–2.70) in GHS,
2.31 (95% CI 1.22–4.34) in TVAS, and 1.36 (95% CI 0.88–2.10) in
CREED, and 1.56 (95% CI 1.15–2.12) in the three cohorts combined.
In the 395 diabetic patients, the Q121 variant predicted cardiovas-
cular events among obese but not among nonobese individuals (HR
5.94 vs. 0.62, P = 0.003 for interaction). A similar synergism was
observed in cross-sectional studies, with age at MI being 3 years
younger in Q121 carriers than in KK homozygotes among obese but
not among nonobese patients (P = 0.035 for interaction).
CONCLUSIONS—The ENPP1 K121Q polymorphism is an inde-
pendent predictor of major cardiovascular events in high-risk
individuals. In type 2 diabetes, this effect is exacerbated by obe-
sity. Future larger studies are needed to conﬁrm our ﬁnding.
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M
orbidity and mortality due to cardiovascular
disease (CVD) are highly prevalent (1), mostly
because of the epidemics of obesity and type 2
diabetes (2–4). Environmental and genetic
factors both contribute to CVD. The genes that are involved
are mostly unknown (5), and only few clues have been
provided about their identities by recent genome-wide as-
sociation studies (6–10). Insulin resistance and related ab-
normalities are among the factors that have been implicated
in the etiology of CVD (11–17). Because insulin resistance is
also under genetic control, the two conditions may share a
common genetic background (18–20), with genes that
contribute to impaired insulin sensitivity being prime can-
didates for a predisposing effect on CVD.
The ectoenzyme nucleotide pyrophosphate phosphodi-
esterase (ENPP1) inhibits insulin receptor signaling (21). A
nonsynonymous polymorphism (K121Q, rs1044498) of the
ENPP1 gene has been described (22), with the Q121 var-
iant determining a gain of function resulting in an in-
creased ability to inhibit insulin receptor signaling (22–24).
This variant has been associated with insulin resistance in
most (22,25–27) but not all (28) large studies. In agreement
with the hypothesis of a common genetic “soil” between
insulin resistance and CVD, the Q121 variant has been also
associated with atherosclerosis-related phenotypes in Eu-
ropean (24,29,30) but not in Brazilian (31) or in Chinese
(32) samples. Most of these associations have been mainly
observed among heavier individuals (25–27,30,33), thereby
suggesting a gene-by-adiposity interaction.
The aim of our study was to investigate the role of the
ENPP1 Q121 variant and its interaction with obesity (i.e.,
BMI $30 kg/m
2) in accelerating major cardiovascular
events in very high-risk individuals.
RESEARCH DESIGN AND METHODS
Study participants
Prospective studies. Sample 1—the Gargano Heart Study, prospective
analysis. The study included 340 whites from Italy with type 2 diabetes
(according to American Diabetes Association 2003 criteria) and coronary
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ORIGINAL ARTICLEartery disease (CAD), as indicated by previous myocardial infarction (MI) or
.50% stenosis of at least one major vessel at coronary angiography, or both.
These individuals were cases of the cross-sectional case-control Gargano
Heart Study (GHS) (30) and were consecutively recruited at the Scientiﬁc
Institute “Casa Sollievo della Sofferenza” from 2001 to 2008 and monitored
until the end of 2009. The only exclusion criterion was the presence of poor
life expectancy due to malignancies. Ten patients became untraceable before
the ﬁrst follow-up visit; therefore, data were available for 330 patients.
Sample 2—the Tor Vergata Atherosclerosis Study. A total of 143 whites
from Italy were consecutively recruited from 2005 at ‘‘Tor Vergata’’ University
Hospital (Rome). They all had been diagnosed with an acute MI according to
the European Society of Cardiology and American Heart Consensus Guide-
lines. Exclusion criteria were the presence of malignancies and a medical
record of diabetes, although 22 study participants (15.6%) were found to have
subclinical diabetes after an oral glucose tolerance test. Because recruitment
is still in progress, only patients who were recruited up to 2007, and as such
underwent at least one follow-up visit, were included in this study. Two
patients became untraceable before the ﬁrst follow-up; therefore, data were
available for 141 patients.
Sample 3—the Cardiovascular Risk Extended Evaluation in Dialysis
database. This study comprises 283 whites with end-stage renal disease
(ESRD), with 231 requiring hemodialysis and 52 receiving long-term ambula-
tory peritoneal dialysis (34). Exclusion criteria were dialysis for less than 6
months, left ventricular ejection fraction ,35%, history of circulatory con-
gestion, and hospitalization for intercurrent illness, including major infections.
No dropouts were observed. Blood samples for DNA extraction were un-
available for 17 subjects; thus, 266 patients were included. Of these, 43 (16.2%)
had diabetes, a proportion similar to that reported by a nationwide epidemi-
ologic study of kidney disease in Italy (35).
Study end point. The end point considered in all three samples was a major
cardiovascular event, deﬁned as nonfatal stroke, nonfatal MI, or cardiovas-
cular death. Information on the occurrence of nonfatal events was sought
yearly from study participants and conﬁrmed by a review of hospital records if
cardiovascular events were reported. If patients did not report to a scheduled
visit, information on the occurrence of cardiovascular events was obtained by
telephone interview, from their primary care physicians, or from death cer-
tiﬁcates. Deaths were ascribed to CVD according to the International Clas-
siﬁcation of Diseases codes: 410.0–410.9, 415.1, 427.4–427.5, 428.0–428.9,
433.1, 434.1, 444.2, 444.8 (9th edition) or I21.0–I21.9, I46.1, I49.0, I50.1, I62.9,
I63.0–I63.9, I71.3 (10th edition).
Cross-sectional study of age at MI. A total of 339 white patients with type 2
diabetes who had survived an MI were studied. They are part of two ongoing
investigations on the genetics of CAD in type 2 diabetes (30,36,37). Of these,
169 were recruited at the Scientiﬁc Institute “Casa Sollievo della Sofferenza” in
San Giovanni Rotondo (Gargano, center east coast of Italy), as cases of the
cross-sectional case-control GHS (29). Most of these patients (n = 160) were
further studied for incident major cardiovascular events in the prospective
GHS (see above). Another 170 were recruited in Boston from the Beth Israel
Deaconess Medical Center (BIDMC) and the Joslin Clinic (which serves as the
BIDMC Diabetes Clinic) as part of an ongoing investigation on the genetics of
CAD in type 2 diabetes that has been described previously (37).
Data collection. All subjects underwent a clinical examination and a stan-
dardizedinterview (at thetimeofrecruitment and ateach subsequenttimepoint,
if applicable), which was identical in all three prospective samples. A fasting
blood sample (collected between 8:00 A.M. and 9:00 A.M.) was obtained from the
prospective study participants and the cross-sectional study participants
recruited in Italy. A random blood sample was obtained from the cross-sectional
study participants recruited in Boston. BMI was calculated by dividing the
weight (in kilograms) by the square of height (in meters). Presence of hyper-
tension was deﬁned as a systolic blood pressure $130 mmHg or diastolic blood
pressure $85 mmHg, or both, or the presence of antihypertensive treatment.
Current and former smokers were considered as one group and compared with
those who never smoked. All study protocols were approved by the local in-
stitutional review boards and performed according to the Helsinki Declaration.
Written informed consent was obtained from each study participant.
Genotyping. DNA was extracted from whole blood by standard methods.
Genotyping of the ENPP1 K121Q polymorphism (rs1044498) was performed
by TaqMan allele discrimination (assay C_16190162_10; Applied Biosystems,
Foster City, CA) on the HT7900 platform (Applied Biosystems). The failure
rate was ,1%. Genotyping quality was assessed by including positive controls
with known genotypes. The agreement rate was .99%. Genotype distribution
was in Hardy-Weinberg equilibrium in all study samples.
Statistical analysis. Patients’ characteristics are reported as mean and SD
for continuous variables and as frequencies and percentages for cate-
goric variables. Comparisons between genotype groups were performed by
Pearson x
2 or Mann-Whitney U tests for continuous or categoric variables,
respectively.
Deviations from Hardy-Weinberg equilibrium were investigated by exact x
2
test. Because of the low number of QQ individuals, only the dominant genetic
model was tested by comparing individuals carrying the K121/Q121 or the
Q121/Q121 genotype (Q121) (i.e., KQ heterozygotes + QQ homozygotes) to
K121 homozygotes (KK). In prospective studies, a time-to-event analysis was
conducted by means of Cox proportional hazards regression models using the
Breslow approach in the case of ties and reported as hazard ratios (HRs) along
with their 95% CI. The time to event was deﬁned as the time between en-
rollment date and the date of the ﬁrst cardiovascular event. For censored
subjects, the time variable was deﬁned as the time between the enrollment
date and the date of the last available clinical data. The assumption of pro-
portionality of the hazards was tested by using scaled Schoenfeld residuals. In
cross-sectional studies, the association between ENPP1 Q121 variant and age
at MI was analyzed by multiple linear regression analysis, and results are given
as b regression coefﬁcients.
Pooled data analyses were performed in an individual patient data meta-
analysis fashion (38) (i.e., adjusting for “study sample”) after excluding
genotype-by-sample interactions. Genotype-by-obesity interaction was tested
by adding a cross-product term to the regression model.
The discriminatory power of prediction models was assessed by estimating
the survival c-index (39) and by measuring the integrated discrimination im-
provement (IDI) (40).
A value of P , 0.05 was considered signiﬁcant. All analyses were performed
using SAS 9.1 software (SAS Institute, Cary, NC).
RESULTS
Characteristics of cohort members at baseline. We
studied three cohorts of subjects who were at very high
risk of major cardiovascular events: the GHS—individuals
with type 2 diabetes and previously diagnosed CAD; the
Tor Vergata Atherosclerosis Study (TVAS)—individuals
from the general population who had experienced an MI;
and the Cardiovascular Risk Extended Evaluation in Di-
alysis (CREED)—individuals with ESRD who required di-
alysis. Clinical characteristics of study subjects at study
entry are summarized in Table 1. No signiﬁcant differences
in baseline characteristics across genotype groups were
observed in any of the three studies.
ENPP1 K121Q polymorphism as a predictor of major
cardiovascular events. The average mean (SD) follow-up
was 37.1 (19.4) months (range 1–91) in the GHS, 30.6 (11.3)
months (range 1–37) in the TVAS, and 36.3 (22.0) months
(range, 1–69) in the CREED. During follow-up, 43 major
cardiovascular events occurred in the GHS, 39 in the
TVAS, and 94 in the CREED, resulting in respective in-
cidence rates of 4.2, 10.8, and 11.7 per 100 person-years
(Table 2). In all studies, incidence rates per 100 person-
years were numerically higher in Q121 carriers than in KK
homozygotes: 5.4 vs. 3.6 in the GHS, 19.2 vs. 8.1 in the
TVAS, and 14.1 vs. 10.8 in the CREED (Table 2). The dif-
ference was signiﬁcant in the TVAS (P = 0.025) and in
a pooled analysis of the three studies (P = 0.005). No dif-
ference in the magnitude of the genetic effect was ob-
served among studies (P = 0.32 for interaction).
In a time-to-event analysis, the HR of cardiovascular
events for Q121 carriers versus KK homozygotes was 1.47
(95% CI 0.80–2.70, P = 0.21) in the GHS, 2.31 (95% CI 1.22–
4.34, P = 0.01) in the TVAS, and 1.36 (95% CI 0.88–2.10, P =
0.16) in the CREED (Fig. 1A, B,a n dC,r e s p e c t i v e l y ;P =0 . 3 2
for gene-by-sample interaction). In a pooled analysis
(i.e., individual patient data meta-analysis) of the three
studies, which included 737 subjects with 176 events, the
HR for Q121 carriers versus KK homozygotes was 1.56
(95% CI 1.15–2.12, P = 0.004; Fig. 1D). Age at study entry
(HR 1.04 [95% CI 1.03–1.06], P , 0.0001), diabetes (2.23
[95% CI 1.50–3.31], P , 0.0001), and smoking status (1.71
[95% CI 1.24–2.36], P = 0.001) were additional predictors of
incident events. BMI (HR 1.03 [95% CI 0.99–1.06], P = 0.08),
hypertension (1.50 [95% CI 0.99–2.27], P = 0.054), and sex
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sociated with increased rate of events, although these did
not reach statistical signiﬁcance. The increased risk of
events associated with the Q121 variant remained signiﬁ-
cant (HR 1.55 [95% CI 1.14–2.12], P = 0.005) after adjusting
for BMI and diabetes, both of which had been reported to
be associated with the Q121 variant (38–40), as well as
after further adjustment for age, sex, hypertension, and
smoking status (HR 1.45 [95% CI 1.05–2.00], P = 0.022).
The addition of the K121Q genotype did not improve the
risk discrimination provided by the predictive model that
included age, sex, BMI, smoking status, hypertension and
diabetes, as indicated by the survival c-index, which went
from 0.704 to 0.713 (P = 0.94), or by the IDI, with 0.42%
improvement (P = 0.16).
Interaction between Q121 variant and obesity in
predicting major cardiovascular events. Given the
previous evidence for an ENPP1-by-obesity interaction in
the modulation of traits related to insulin resistance (25–
27,29,30,39–41), we investigated this hypothesis in our
study. In the GHS, which entirely consisted of patients
with type 2 diabetes, we indeed observed a signiﬁcant in-
teraction between the Q121 variant and obesity. An asso-
ciation between the variant and risk of events was present
among the 159 subjects who had a BMI $30 kg/m
2 (HR
3.56 [95% CI 1.21–10.5], P = 0.02), but not among the 171
individuals who had a BMI ,30 kg/m
2 (0.91 [95% CI 0.40–
2.06], P = 0.82; P = 0.039 for interaction).
No evidence of gene-by-obesity interaction was instead
observed in the TVAS (P = 0.53) and the CREED (P = 0.41).
Because approximately 85% of these two cohorts con-
sisted of nondiabetic individuals, we hypothesized that the
genotype-by-obesity interaction might be speciﬁc to di-
abetes. Indeed, a pattern consistent with such an effect
was also observed in these two studies when the analysis
was restricted to individuals with diabetes, even though
the small sample size prevented statistical signiﬁcance
(data not shown).
Thus, we further investigated the Q121-by-obesity in-
teraction in a pooled analysis of the three studies after
stratiﬁcation by diabetes status. In the diabetic stratum (n =
395), the Q121 variant was associated with an increased risk
of incident events among the 177 obese (Fig. 2A)b u tn o t
among the 218 nonobese (Fig. 2B) individuals, with adjusted
HRs of 5.94 (95% CI 1.88–18.78, P = 0.002) vs. 0.62 (95% CI
0.32–1.24, P = 0.18). The interaction between the Q121
variant and obesity was signiﬁcant (P = 0.003). By contrast,
no evidence of interaction was observed in the nondiabetic
stratum (n =3 4 4 ,P = 0.26), with adjusted HRs of 0.82 (95%
CI 0.22–3.11, P = 0.77) in the 39 obese individuals and 1.85
(95% CI 1.18–2.90, P = 0.008) in the 305 nonobese subjects.
Among obese diabetic individuals, the addition of the
K121Q genotype to the multivariable model produced a slight
improvement from 0.802 to 0.831 in risk discrimination when
this was assessed by the survival c-index (P = 0.81). A much
larger effect, approaching statistical signiﬁcance, was ob-
served when the improvement was assessed by IDI with
a 4.56% improvement (95% CI 20.27 to 9.42, P =0 . 0 9 ) .
TABLE 1
Clinical features of very high-risk individuals in the three
prospective studies
Variables Whole sample KK Q121
GHS n = 330 n = 222 n = 108
Male 68.8 68.0 70.4
Age (years) 64 (8) 64 (8) 65 (7)
Smokers 47.2 49.8 41.8
BMI (kg/m
2) 30.2 (4.8) 30.1 (4.6) 30.5 (5.2)
Hypertension 77.8 78.0 77.4
Diabetes 100 100 100
TVAS n = 141 n = 102 n =3 9
Male 83.7 84.2 82.1
Age (years) 62 (10) 62 (10) 63 (9)
Smokers 75.2 73.3 82.0
BMI (kg/m
2) 28.0 (3.7) 28.4 (3.8) 27.0 (3.4)
Hypertension 98.6 98.0 100.0
Diabetes 15.6 16.8 12.8
CREED n = 266 n = 188 n =7 8
Male 56.0 52.1 65.4
Age (years) 61 (15) 60 (16) 64 (14)
Smokers 40.0 38.3 43.6
BMI (kg/m
2) 24.9 (4.4) 24.9 (4.6) 24.8 (4.0)
Hypertension 72.9 73.9 70.5
Diabetes 16.2 16.5 15.4
Data are expressed as absolute numbers, percentage, or mean (SD).
TABLE 2
Incidence of major cardiovascular events in GHS, TVAS, and CREEDS
N Person-years Nonfatal MI Nonfatal stroke CV death Total events Incidence rate* P
GHS
All 330 1,027 3 8 32 43 4.2
KK 222 694 1 3 21 25 3.6
Q121 108 333 2 5 11 18 5.4 0.22
TVAS
All 141 361 20 13 6 39 10.8
KK 102 272 11 9 2 22 8.1
Q121 39 89 9 4 4 17 19.2 0.025
CREED
All 266 804 1 10 83 94 11.7
KK 188 592 1 8 55 64 10.8
Q121 78 212 0 2 28 30 14.1 0.225
GHS+TVAS+CREED
All 737 2,192 24 31 121 176 8.1
KK 512 1,558 13 20 78 111 7.0
Q121 225 634 11 11 43 65 10.9 0.005
*Per 100 person-years. CV, cardiovascular.
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at MI in cross-sectional studies. To seek replication of
the gene-by-obesity interaction observed in patients with
diabetes, we analyzed the association between the Q121
variant and age at MI in two cross-sectional samples of
individuals with type 2 diabetes who had had a previous
MI. One sample was from the Gargano area in Italy, the
other was from Boston. Salient clinical features of the
FIG. 1. Kaplan-Meier survival curves are shown for major cardiovascular events in GHS (A), TVAS (B), and CREED (C). D: Estimates generated by
Cox regression in the pooled analysis are shown.
FIG. 2. Survival curves for major cardiovascular events in obese (A) and nonobese (B) patients with type 2 diabetes. Curves are estimates
generated by Cox regression in the pooled analysis of the three prospective studies.
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signiﬁcant genotype-by-sample interaction was observed
in the association with age at MI (P = 0.11), pooled anal-
yses were performed by adjusting for “study sample.” To
make the analysis comparable to that of prospective stud-
ies, sex, smoking status, hypertension, and BMI, but not
age (due to its collinearity with age at MI—and diabetes—
because all study participants were diabetic) were in-
cluded as covariates. Among obese subjects, 64 Q121
carriers had had the MI almost 3 years earlier than the
124 KK homozygotes, at 54.5 (9.6) vs. 57.2 (8.9) years of
age (P = 0.035). In contrast, no signiﬁcant difference in
age at MI was observed among nonobese subjects: 59.2
(10.5) in 41 Q121 carriers versus 57.2 (10.4) in 110 KK
homozygotes (P =0 . 1 6 ;P = 0.025 value for Q121-by-
obesity interaction).
Virtually identical results were obtained when duration
of diabetes was also added to the multivariate model, with
Q121 carriers having had an MI at a signiﬁcantly younger
age than KK individuals among obese (P = 0.039) but not
among nonobese (P = 0.20) individuals (P = 0.032 for in-
teraction). In addition, when BMI was considered as a
continuous trait, it was inversely related to the age at MI
among Q121 carriers (b = 20.44 [95% CI 20.75 to 20.12],
P = 0.008; Fig. 3A), but not among KK individuals (b =
20.17 [95% CI 20.41 to 0.07], P = 0.16; P = 0.069; for Q121-
by-BMI interaction; Fig. 3B).
DISCUSSION
Our results indicate that the ENPP1 K121Q polymorphism
predicts acceleration of major cardiovascular events
in very high-risk patients. The increased risk conferred by
the Q121 variant is independent of that of age, sex, BMI,
diabetes, and cigarette smoking. Our ﬁndings are in
agreement with a previous cross-sectional study of 445 MI
survivors from Central Europe (29). By contrast, case-control
genome-wide association studies reported that a single
nucleotide polymorphism (SNP, rs7767502), which is in
perfect linkage disequilibrium with the ENPP1 K121Q
polymorphism, was not associated with CAD (6–10). Sev-
eral differences between our study and the genome-wide
association studies, such as the prospective versus cross-
sectional designs, the different end points under inves-
tigation, and the different baseline cardiovascular risk,
with only the patients enrolled in our study being very
high-risk as per selection criteria, might be responsible for
this apparent discordance.
An additional important result of our study is that the
effect of the Q121 variant was modulated by obesity in
diabetic patients among whom the risk of incident events
was ﬁve times higher in Q121 than in KK genotype carriers.
Although not the aim of our study, one can infer that obese
individuals (Fig. 2A) as a whole tend to have a lower risk
of future cardiovascular events than nonobese patients
(Fig. 2B; adjusted HR 0.68 [95% CI 0.411–1.124], P = 0.13).
This paradoxic protective effect of obesity resembles that
observed in patients with CAD (41), ESRD (42), heart
failure (43), and older age (44), all conditions heavily over-
represented in our samples. In this context, the Q121
variant seems to eliminate the paradoxic protective effect
of obesity.
An important ﬁnding was that the Q121 variant-by-
obesity interaction observed in the prospective study was
replicated in a cross-sectional study on age at MI in di-
abetic patients. Information on the K121Q genotypes
tended to improve risk prediction in these patients when
the improvement was measured by the IDI, the approach
that is currently favored to evaluate predictive ability in-
crease conferred by a new marker when added to a well-
performing model (39). Thus, pending further validation in
larger studies, one can hypothesize clinical implementa-
tion of the Q121 variant as a marker of early cardiovas-
cular events among obese diabetic patients. Given the
increasing incidence worldwide of both obesity and di-
abetes (2–4) and the poor ability to stratify cardiovascular
risk among diabetic patients, a large sector of society
would be likely to beneﬁt in the future from the availability
of such a test.
The synergistic effect of the genetic marker and obesity
in the modulation of cardiovascular risk resembles results
repeatedly reported in the risk modulation of insulin re-
sistance and related traits (25–27,30,33,45–49). Placed in
a broader perspective, this is an excellent example of ge-
netic heterogeneity (i.e., different genetic effects being at
play in different population subgroups) and clearly il-
lustrates how accounting for such heterogeneity may be
critical to dissect the genetic architecture of multifactorial
diseases.
Understanding the mechanisms through which the Q121
variant is associated with CVD is beyond the scope of this
study. However, one can speculate that the Q121 variant
exacerbates cardiovascular risk by inducing systemic in-
sulin resistance (22,25–27) and proatherogenic phenotypes
TABLE 3
Clinical features of patients with type 2 diabetes who survived an
MI in the two cross-sectional studies
Whole sample KK Q121
Gargano n = 169 n = 112 n =5 7
Male (%) 70.4 72.3 66.7
Age (years) 64 (9) 64 (9) 64 (8)
Smokers (%) 44.0 47.6 37.0
BMI (kg/m
2) 30.7 (4.8) 30.6 (4.6) 30.9 (5.3)
Hypertension (%) 86.9 89.3 82.1
Duration of diabetes
(years) 14.2 (9.5) 14.7 (9.9) 13.3 (8.5)
HbA1c (%) 8.6 (2.0) 8.6 (1.8) 8.5 (2.2)
Treatment of hyperglycemia
Diet alone (%) 7.2 5.4 10.9
Oral hypoglycemic
agents (%) 40.4 38.7 43.6
Insulin 6 oral
hypoglycemic
agents (%) 52.4 55.9 45.5
Boston n = 170 n = 122 n =4 8
Male (%) 72.4 73.3 70.8
Age (years) 64.6 (7.9) 64.7 (7.8) 64.3 (8.1)
Smokers (%) 69.3 66.9 75.6
BMI (kg/m
2) 31.8 (5.9) 31.3 (5.6) 33.1 (6.4)
Hypertension (%) 78.2 77.0 81.3
Duration of diabetes
(years) 12.5 (9.3) 11.8 (9.4) 14.1 (9.1)
HbA1c (%) 7.4 (1.4) 7.5 (1.5) 7.3 (1.3)
Treatment of hyperglycemia
Diet alone (%) 5.3 4.1 8.3
Oral hypoglycemic
agents (%) 42.9 47.5 31.3
Insulin 6 oral
hypoglycemic
agents (%) 51.8 48.4 60.4
Data are expressed as number, percentage, or mean (SD).
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effect on insulin-dependent endothelial function, as sug-
gested by the observation that human endothelial cells
carrying the Q121 variant show impaired insulin receptor
signaling and, most importantly, reduced release of nitric
oxide (24), a potent vasodilator whose deﬁciency is an
established early step in the pathway development of
atherosclerosis (50).
One can hypothesize that the interaction between the
Q121 variant and obesity is sustained by the different sites
of action on the insulin-signaling pathway. Although ENPP1
acts at the insulin receptor level (21,23), obesity acts by
different mechanisms, mostly at a postreceptor level (51).
It is, therefore, possible that postreceptor insulin-signaling
abnormalities are necessary for the Q121 variant to be fully
effective in inducing insulin resistance and, eventually, re-
lated clinical outcomes.
The three cohorts of very high-risk individuals that we
studied were quite different from each other: one com-
prised only patients with type 2 diabetes and CAD, another
included patients with a previous MI who did not have
frank type 2 diabetes, and the third included only patients
with ESRDs. Despite such apparent phenotypic heteroge-
neity, the effect of the Q121 variant was not heterogeneous
across the three studies. Not only did this allow us to an-
alyze the three cohorts together, increasing statistical power,
but it also suggests that our ﬁndings may be generalizable
to all high-risk patients, irrespective of their background
clinical characteristics. Whet h e rt h ep r e d i c t i v er o l eo f
the Q121 variant extends to situations characterized by
a more moderate cardiovascular risk remains to be
determined.
We acknowledge that, mainly because of the relatively
small size of our samples, the signiﬁcance level of our
ﬁndings is still compatible with a false-positive result.
However, this seems unlikely given that the association
between Q121 was not heterogeneous across the three
cohorts and, importantly, was further conﬁrmed in cross-
sectional studies as far as the interaction with obesity in
diabetic patients is concerned. We also acknowledge that
due to the relatively small sample size of the studies that
we analyzed, we cannot exclude that the gene-by-obesity
interaction that we observed among diabetic patients also
occurs among nondiabetic individuals, as is the case for
the modulation of insulin resistance (25–27). Therefore,
our ﬁndings need further replication in larger samples
before they can be considered as established. Finally, be-
cause this study was entirely performed in individuals of
European ancestry, we do not know whether our ﬁndings
can be extended to populations of different race.
In conclusion, pending conﬁrmation in further larger
studies, the Q121 variant has the potential to become
a clinical tool for identifying those very high-risk patients
who are especially prone to major cardiovascular events
and need, therefore, to be targeted with speciﬁc and even
more aggressive preventive strategies.
ACKNOWLEDGMENTS
This study was partly supported by the Italian Ministry of
Health (“Ricerca Corrente 2009 and 2010”) (to S.P. and
V.T.), by Fondazione Roma (“Sostegno alla ricerca scien-
tiﬁca biomedica 2008”) (to V.T.), and by the National Insti-
tutes of Health Grants HL73168 (to A.D.) and DK36836 to
the Genetics Core of the Diabetes & Endocrinology Re-
search Center at the Joslin Diabetes Center.
No potential conﬂicts of interest relevant to this article
were reported.
S.B. designed the study; acquired, analyzed, and inter-
preted the data; and wrote the manuscript. S.R. and S.P.
acquired, analyzed, and interpreted the data and reviewed
and edited the manuscript. B.S., C.P., A.F., A.P., D.L., A.T.,
Y.-Y.Z., and G.D.S. acquired data and reviewed the man-
uscript. F.M. reviewed the manuscript. G.T., R.X., D.M.,
F.A., R.L., E.V.G., and T.H.H. acquired data and reviewed
the manuscript. M.C. acquired and analyzed the data and
reviewed and edited the manuscript. S.D.C. acquired and
interpreted the data and reviewed the manuscript. F.P.
k k
FIG. 3. Linear regression between BMI and age at MI in diabetic patients with Q121 (A) and KK (B) genotypes. Data are obtained by individual
data meta-analysis of the two cross-sectional studies from Gargano and Boston.
S. BACCI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 1005acquired and analyzed the data and reviewed and edited
the manuscript. C.Z. and M.F. acquired data and reviewed
and edited the manuscript. A.D. and V.T. designed the
study, analyzed and interpreted the data, and wrote the
manuscript.
The authors are grateful to Celeste Amundsen, Erin
Murphy, and Elisabeth Goheen (Joslin Diabetes Center,
Boston, MA) for their technical help and acknowledge the
invaluable contribution by the individuals who partici-
pated in this study.
REFERENCES
1. Lloyd-Jones D, Adams RJ, Brown TM, et al.; Writing Group Members;
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Heart disease and stroke statistics—2010 update: a report
from the American Heart Association. Circulation 2010;121:e46–e215
2. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med
2006;12:75–80
3. Goya Wannamethee S, Gerald Shaper A, Whincup PH, Walker M. Over-
weight and obesity and the burden of disease and disability in elderly men.
Int J Obes Relat Metab Disord 2004;28:1374–1382
4. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all
Americans become overweight or obese? Estimating the progression and
cost of the US obesity epidemic. Obesity (Silver Spring) 2008;16:2323–2330
5. Hamsten A, Eriksson P. Identifying the susceptibility genes for coronary
artery disease: from hyperbole through doubt to cautious optimism. J In-
tern Med 2008;263:538–552
6. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on
chromosome 9 associated with coronary heart disease. Science 2007;316:
1488–1491
7. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on
chromosome 9p21 affects the risk of myocardial infarction. Science 2007;
316:1491–1493
8. Samani NJ, Erdmann J, Hall AS, et al.; WTCCC and the Cardiogenics
Consortium. Genomewide association analysis of coronary artery disease.
N Engl J Med 2007;357:443–453
9. Erdmann J, Grosshennig A, Braund PS, et al.; Italian Atherosclerosis,
Thrombosis, and Vascular Biology Working Group; Myocardial Infarction
Genetics Consortium; Wellcome Trust Case Control Consortium; Cardio-
genics Consortium. New susceptibility locus for coronary artery disease
on chromosome 3q22.3. Nat Genet 2009;41:280–282
10. Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF,
Purcell S, et al. Genome-wide association of early-onset myocardial in-
farction with common single polymorphisms, common copy number var-
iants, and rare copy number variants. Nat Genet 2009;41:334–341
11. Reaven GM. Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes 1988;37:1595–1607
12. Howard G, O’Leary DH, Zaccaro D, et al.; The Insulin Resistance Athero-
sclerosis Study (IRAS) Investigators. Insulin sensitivity and atherosclero-
sis. Circulation 1996;93:1809–1817
13. Hedblad B, Nilsson P, Engström G, Berglund G, Janzon L. Insulin re-
sistance in non-diabetic subjects is associated with increased incidence of
myocardial infarction and death. Diabet Med 2002;19:470–475
14. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. Insulin
resistance, the metabolic syndrome, and incident cardiovascular events in
the Framingham Offspring Study. Diabetes 2005;54:3252–3257
15. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic
kidney disease in U.S. adults. Ann Intern Med 2004;140:167–174
16. De Cosmo S, Trevisan R, Minenna A, et al. Insulin resistance and the
cluster of abnormalities related to the metabolic syndrome are associated
with reduced glomerular ﬁltration rate in patients with type 2 diabetes.
Diabetes Care 2006;29:432–434
17. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of
insulin. Endocr Rev 2007;28:463–491
18. Pedersen O. Genetics of insulin resistance. Exp Clin Endocrinol Diabetes
1999;107:113–118
19. Rich SS, Bowden DW, Haffner SM, et al.; Insulin Resistance Atheroscle-
rosis Study Family Study. Identiﬁcation of quantitative trait loci for glucose
homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family
Study. Diabetes 2004;53:1866–1875
20. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A.
Heritability of insulin secretion, peripheral and hepatic insulin action, and
intracellular glucose partitioning in young and old Danish twins. Diabetes
2005;54:275–283
21. Goldﬁne ID, Maddux BA, Youngren JF, et al. The role of membrane gly-
coprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phos-
phodiesterase 1 in the pathogenesis of insulin resistance and related
abnormalities. Endocr Rev 2008;29:62–75
22. Pizzuti A, Frittitta L, Argiolas A, et al. A polymorphism (K121Q) of the
human glycoprotein PC-1 gene coding region is strongly associated with
insulin resistance. Diabetes 1999;48:1881–1884
23. Costanzo BV, Trischitta V, Di Paola R, et al. The Q allele variant (GLN121)
of membrane glycoprotein PC-1 interacts with the insulin receptor and
inhibits insulin signaling more effectively than the common K allele variant
(LYS121). Diabetes 2001;50:831–836
24. Bacci S, Di Paola R, Menzaghi C, et al. ENPP1 Q121 variant, increased
pulse pressure and reduced insulin signaling, and nitric oxide synthase
activity in endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:1678–
1683
25. Abate N, Chandalia M, Satija P, et al. ENPP1/PC-1 K121Q polymorphism
and genetic susceptibility to type 2 diabetes. Diabetes 2005;54:1207–
1213
26. Stolerman ES, Manning AK, McAteer JB, et al. Haplotype structure of the
ENPP1 Gene and Nominal Association of the K121Q missense single nu-
cleotide polymorphism with glycemic traits in the Framingham Heart
Study. Diabetes 2008;57:1971–1977
27. Baratta R, Rossetti P, Prudente S, et al. Role of the ENPP1 K121Q poly-
morphism in glucose homeostasis. Diabetes 2008;57:3360–3364
28. Grarup N, Urhammer SA, Ek J, et al. Studies of the relationship between
the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance
and obesity in 7,333 Danish white subjects. Diabetologia 2006;49:2097–
2104
29. Endler G, Mannhalter C, Sunder-Plassmann H, et al. The K121Q poly-
morphism in the plasma cell membrane glycoprotein 1 gene predisposes to
early myocardial infarction. J Mol Med 2002;80:791–795
30. Bacci S, Ludovico O, Prudente S, et al. The K121Q polymorphism of the
ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phe-
notypes, including earlier onset of type 2 diabetes and myocardial in-
farction. Diabetes 2005;54:3021–3025
31. Moehlecke M, Kramer CK, Leitão CB, et al. [ENPP1 K121Q polymorphism
and ischemic heart disease in diabetic patients]. Arq Bras Cardiol 2010;94:
157–161, 168–173, 159–163
32. Chen MP, Chung FM, Chang DM, et al. ENPP1 K121Q polymorphism is not
related to type 2 diabetes mellitus, features of metabolic syndrome, and
diabetic cardiovascular complications in a Chinese population. Rev Diabet
Stud 2006;3:21–30
33. De Cosmo S, Minenna A, Zhang YY, et al. Association of the Q121 variant
of ENPP1 gene with decreased kidney function among patients with type 2
diabetes. Am J Kidney Dis 2009;53:273–280
34. Testa A, Spoto B, Tripepi G, et al. The GLU298ASP variant of nitric oxide
synthase interacts with asymmetric dimethyl arginine in determining car-
diovascular mortality in patients with end-stage renal disease. J Hypertens
2005;23:1825–1830
35. Panzetta G, Basile C, Santoro A, et al. Diabetics on dialysis in Italy: a na-
tionwide epidemiological study. Nephrol Dial Transplant 2008;23:3988–
3995
36. Prudente S, Hribal ML, Flex E, et al. The functional Q84R polymorphism of
mammalian Tribbles homolog TRB3 is associated with insulin resistance
and related cardiovascular risk in Caucasians from Italy. Diabetes 2005;54:
2807–2811
37. Doria A, Wojcik J, Xu R, et al. Interaction between poor glycemic control
and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA
2008;300:2389–2397
38. Olkin I, Sampson A. Comparison of meta-analysis versus analysis of vari-
ance of individual patient data. Biometrics 1998;54:317–322
39. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in
survival analysis: model speciﬁc population value and conﬁdence interval
estimation. Stat Med 2004;23:2109–2123
40. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the
added predictive ability of a new marker: from area under the ROC curve to
reclassiﬁcation and beyond. Stat Med 2008;27:157–172; discussion 207–212
41. Kang X, Shaw LJ, Hayes SW, et al. Impact of body mass index on cardiac
mortality in patients with known or suspected coronary artery disease
undergoing myocardial perfusion single-photon emission computed to-
mography. J Am Coll Cardiol 2006;47:1418–1426
42. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epide-
miology of cardiovascular risk factors in maintenance dialysis patients.
Kidney Int 2003;63:793–808
43. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiol-
ogy of conventional cardiovascular risk factors in patients with chronic
heart failure. J Am Coll Cardiol 2004;43:1439–1444
ENPP1 GENE AND CARDIOVASCULAR DISEASE
1006 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.org44. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect
of age on the association between body-mass index and mortality. N Engl J
Med 1998;338:1–7
45. Meyre D, Bouatia-Naji N, Tounian A, et al. Variants of ENPP1 are associ-
ated with childhood and adult obesity and increase the risk of glucose
intolerance and type 2 diabetes. Nat Genet 2005;37:863–867
46. McAteer JB, Prudente S, Bacci S, et al.; ENPP1 Consortium. The ENPP1
K121Q polymorphism is associated with type 2 diabetes in European
populations: evidence from an updated meta-analysis in 42,042 subjects.
Diabetes 2008;57:1125–1130
47. Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect
on T2DM and cardiovascular risk. Nat Rev Endocrinol 2009;5:682–693
48. Bochenski J, Placha G, Wanic K, et al. New polymorphism of ENPP1 (PC-1)
is associated with increased risk of type 2 diabetes among obese individuals.
Diabetes 2006;55:2626–2630
49. Cauchi S, Nead KT, Choquet H, et al. The genetic susceptibility to type 2
diabetes may be modulated by obesity status: implications for association
studies. BMC Med Genet 2008;9:45
50. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis.
Circulation 2004;109(Suppl. 1):III27–III32
51. Abate N, Chandalia M, Di Paola R, Foster DW, Grundy SM, Trischitta V.
Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodies-
terase 1 as a ‘gatekeeper’ of insulin receptors. Nat Clin Pract Endocrinol
Metab 2006;2:694–701
S. BACCI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 1007